CDK4 and breast carcinoma: The use of CDK4/6i (palbociclib, ribociclib, and abemaciclib) in clinical studies with humans with breast cancer resulted from this data as well as the animal genetic studies previously mentioned (Pandey et al., 2019[90]; Yang et al., 2020[125]).